WALD Waldencast plc
Price Chart
Executive Summary
Obagi Medical, a Waldencast subsidiary, presented interim clinical and real-world data at the Music City SCALE meeting for its NU-GEN Cellular Renewal Serum and Saypha MagIQ hyaluronic acid filler. The data shows strong practitioner adoption (94% believe MagIQ complements their current fillers) and clinical efficacy (NU-GEN clinically proven to reduce perceived skin age by up to six years). While the data is positive for the brand's pipeline, it is early-stage (interim, non-pivotal) and does not represent a near-term revenue catalyst for Waldencast.
Actionable Insight
The press release contains no hard financial data or guidance. The clinical and real-world data are positive for brand perception but do not constitute a near-term catalyst. Monitor for future FDA registration updates on the filler program or quarterly earnings for revenue contribution from these products.
Key Facts
- Interim data from ALOHA program: 94% of injectors believe Obagi Saypha MagIQ complements their current filler options.
- NU-GEN Cellular Renewal Serum clinically proven to reduce perceived skin age by up to six years in a 12-week study.
- 43% of patients evaluating MagIQ also evaluating Obagi skincare, indicating cross-selling potential.
- Data presented at Music City SCALE meeting (May 13-17, 2026) — a medical conference, not a regulatory milestone.
- Obagi Medical is the fastest-growing professional skincare brand in the U.S. in 2024, per the press release.
Financial Impact
No financial figures disclosed. Data is early-stage and non-binding; no revenue or earnings impact quantified.
Risk Factors
- Data is interim and non-pivotal; full results may differ.
- No FDA approval or regulatory milestone achieved — filler program still in registration phase.
- Waldencast is a small-cap ($209M) with limited liquidity; stock may not react to early-stage data.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295810 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 1, 2026
12d ago
|
Press Release
| $1.83 $1.72 | ▼ −6.01% | ▼ −3.26% | $1.86 (+1.64%) |
|
May 15, 2026
29d ago
|
Press Release
| $1.47 $1.30 | ▼ −11.56% | ▼ −12.53% | $1.86 (+26.53%) |
|
May 14, 2026
4w ago
|
Press Release
| $1.63 $1.30 | ▼ −20.25% | ▼ −19.53% | $1.86 (+14.11%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $0.7630 $1.04 | ▲ +36.30% | ▲ +33.19% | $1.86 (+143.77%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $1.33 $1.02 | ▼ −23.31% | ▼ −21.10% | $1.86 (+39.85%) |
|
Mar 13, 2026
13w ago
|
Press Release
| $1.58 $1.19 | ▲ +25.00% | ▲ +22.88% | $1.86 (−17.72%) |
|
Mar 11, 2026
13w ago
|
Press Release
| $1.46 $1.33 | ▼ −8.90% | ▼ −7.93% | $1.86 (+27.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access